全球胰臟外分泌功能不全市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計外分泌胰臟功能不全的市場規模將從 2025 年的 36.9 億美元成長到 2034 年的 62.3 億美元，2026 年至 2034 年的複合年成長率為 5.99%。

受胃腸道和胰臟疾病日益普遍的推動，全球外分泌性胰臟功能不全市場正穩定成長。外分泌性胰臟功能不全是指胰臟無法產生足夠的消化酶，導致營養吸收不足。人們對胃腸道健康的日益重視以及診斷能力的提升，促使更多患者尋求治療，從而推動了市場成長。

推動該市場發展的主要因素是慢性胰臟炎、囊腫纖維化和胰臟癌等疾病發生率的上升。這些疾病通常會導致酵素缺乏，需要進行酵素替代療法。製藥公司也致力於開發更有效的胰酶替代療法，這進一步促進了市場成長。

未來幾年，隨著醫療體係日益重視早期診斷和治療方法，市場預計將持續成長。製劑技術的進步以及發展中地區醫療服務可近性的提高也將推動市場成長。此外，旨在改善消化酵素療法的持續臨床研究將為外分泌性胰臟功能不全的治療創造新的機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球外分泌性胰臟功能不全市場：依治療方式分類

• 市場分析、洞察與預測
• 營養管理
• 胰酵素替代療法（PERT）

第5章：全球外分泌性胰臟功能不全市場：依藥物類型分類

• 市場分析、洞察與預測
• 克瑞翁
• Zenpep
• 龐克種族
• Viokace
• 其他藥物類型

第6章：全球外分泌性胰臟功能不全市場：依症狀分類

• 市場分析、洞察與預測
• 腹痛
• 便秘
• 腹瀉
• 脂肪瀉
• 減肥
• 其他症狀

第7章 全球外分泌胰臟功能不全市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球外分泌胰臟功能不全市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott Laboratories
  • AbbVie
  • Digestive Care
  • Essential Pharma
  • Nestle
  • Nordmark Pharma
  • Sun Pharmaceutical Industries
  • Viatris
  • Vivus
  • Zentiva Pharma UK

The Exocrine Pancreatic Insufficiency Market size is expected to reach USD 6.23 Billion in 2034 from USD 3.69 Billion (2025) growing at a CAGR of 5.99% during 2026-2034.

The global exocrine pancreatic insufficiency market is growing steadily due to the increasing prevalence of digestive disorders and pancreatic diseases. Exocrine pancreatic insufficiency occurs when the pancreas does not produce enough digestive enzymes, leading to poor nutrient absorption. Rising awareness about gastrointestinal health and improved diagnostic capabilities are encouraging more patients to seek treatment, contributing to market growth.

A key driver of this market is the increasing incidence of conditions such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. These diseases often result in enzyme deficiencies that require enzyme replacement therapies. Pharmaceutical companies are also focusing on developing more effective pancreatic enzyme replacement treatments, which is further boosting the market.

In the coming years, the market is expected to expand as healthcare systems focus more on early diagnosis and improved treatment options. Advancements in drug formulations and growing access to healthcare services in developing regions will likely support market expansion. Additionally, ongoing clinical research aimed at improving digestive enzyme therapies will create new opportunities in the exocrine pancreatic insufficiency treatment landscape.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)

By Drug Type

• Creon
• Zenpep
• Pancreaze
• Viokace
• Other Drug Types

By Symptom

• Abdominal Pain
• Constipation
• Diarrhea
• Fatty Stools
• Weight Loss
• Other Symptoms

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Abbott Laboratories, AbbVie, Digestive Care, Essential Pharma, Nestle, Nordmark Pharma, Sun Pharmaceutical Industries, Viatris, Vivus, Zentiva Pharma UK
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Nutritional Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Enzyme Replacement Therapy (PERT) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Creon Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Zenpep Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pancreaze Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Viokace Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Drug Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY SYMPTOM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Symptom
• 6.2. Abdominal Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diarrhea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Fatty Stools Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Weight Loss Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment
  • 8.2.2 By Drug Type
  • 8.2.3 By Symptom
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment
  • 8.3.2 By Drug Type
  • 8.3.3 By Symptom
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment
  • 8.4.2 By Drug Type
  • 8.4.3 By Symptom
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment
  • 8.5.2 By Drug Type
  • 8.5.3 By Symptom
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment
  • 8.6.2 By Drug Type
  • 8.6.3 By Symptom
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 AbbVie
  • 10.2.3 Digestive Care
  • 10.2.4 Essential Pharma
  • 10.2.5 Nestle
  • 10.2.6 Nordmark Pharma
  • 10.2.7 Sun Pharmaceutical Industries
  • 10.2.8 Viatris
  • 10.2.9 Vivus
  • 10.2.10 Zentiva Pharma UK